(Q85783639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

main subject

cervix uterine cancer

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

John B McIntyre

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jackson S Wu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Peter S Craighead

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tien Phan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Susan P Lees-Miller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Prafull Ghatage

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Anthony M Magliocco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Corinne M Doll

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

22 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

409-414

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Molecular profiling for personalized cancer care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Exploiting the PI3K/AKT pathway for cancer drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Mutation of the PIK3CA oncogene in human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

High frequency of mutations of the PIK3CA gene in human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

The PIK3CA gene is mutated with high frequency in human breast cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Mutation of the PIK3CA gene in ovarian and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Oncogenic PI3K and its role in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

PIK3CA mutations in head and neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

The null hypothesis significance test in health sciences research (1995-2006): statistical analysis and interpretation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.12.019

10.1016/J.YGYNO.2012.12.019

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23266353%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference